Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoXSWX:BMY 72 Intrinsic Value: Projected FCF is CHF55.49 as of Sep. 05, 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 72/100 and a GF Value™ of CHF45.97 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 634 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 68.93% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Bristol-Myers Squibb Co's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:BMY'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.61 Med: 1.3 Max: 2.52
Current: 0.97
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Bristol-Myers Squibb Co was 2.52. The lowest was 0.61. And the median was 1.30.
XSWX:BMY's Price-to-Projected-FCF is ranked better than 68.93% of 634
companies
in the Drug Manufacturers industry
Industry Median: 1.57
vs XSWX:BMY: 0.97
Bristol-Myers Squibb Co (XSWX:BMY) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Bristol-Myers Squibb Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
54.34
/
59.925204330764
=
0.91
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Intrinsic Value: Projected FCF Related Terms
Bristol-Myers Squibb Co Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Bristol-Myers Squibb Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Intrinsic Value: Projected FCF Chart
XSWX:BMY vs PFE, GILD, AMGN: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Price-to-Projected-FCF falls into.
Bristol-Myers Squibb Co Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF55.49 mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Intrinsic Value: Projected FCF of CHF55.49 as of Sep. 05, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Bristol-Myers Squibb Co and its competitors. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #197 out of 634 companies in the Drug Manufacturers industry, placing it in the top 31.1%.
Is Bristol-Myers Squibb Co's Intrinsic Value: Projected FCF too high?
Bristol-Myers Squibb Co's current Intrinsic Value: Projected FCF is CHF55.49. Based on the distribution chart, Bristol-Myers Squibb Co ranks #197 out of 634 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Intrinsic Value: Projected FCF compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #197 out of 634 companies for Intrinsic Value: Projected FCF. This puts Bristol-Myers Squibb Co in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.57, based on 634 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Intrinsic Value: Projected FCF is CHF55.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.97, compared to a current price of CHF54.34 — trading 18.2% above its estimated fair value. The current Intrinsic Value: Projected FCF is CHF55.49. Bristol-Myers Squibb Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Intrinsic Value: Projected FCF is CHF55.49 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF54.34 is trading 18.2% above its estimated GF Value™ of CHF45.97.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for XSWX:BMY:
Intrinsic Value: Projected FCF: CHF55.49
GF Value™: CHF45.97 vs. price of CHF54.34 (18.2% above fair value)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
72GF Score
Get the complete analysis for XSWX:BMY
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
